Press Release: Novartis Fabhalta(R) shows -2-

Novartis

95.89 CHF -0.98%

• Charts
• News
• Analysen

Kaufen Verkaufen

actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA== Instagram.

References

1. Novartis. Data on file.

2. Clinicaltrials.gov. NCT05630001. Single Arm, Open Label Trial With

Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of

Anti-C5 Who Switch to Iptacopan. (APPULSE). Available from:

https://clinicaltrials.gov/study/NCT05630001 Accessed May, 2025.

3. Montan I, Löwe B, Cella D, Mehnert A, Hinz A. General Population

Norms for the Functional Assessment of Chronic Illness Therapy

(FACIT)-Fatigue Scale. Value Health. 2018;21(11):1313-1321.

doi:10.1016/j.jval.2018.03.013

4. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer

patients compared with fatigue in the general United States population.

Cancer. 2002;94(2):528-538. doi:10.1002/cncr.10245

5. Peffault de Latour R, Röth A, Kulasekararaj AG, et al. Oral

Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J

Med. 2024;390(11):994-1008. doi:10.1056/NEJMoa2308695

6. Cançado RD, Araújo ADS, Sandes AF, et al. Consensus statement

for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria.

Hematol Transfus Cell Ther. 2021;43(3):341-348.

7. Dingli D, Matos JE, Lehrhaupt K, et al. The burden of illness in patients

with paroxysmal nocturnal hemoglobinuria receiving treatment with the

C5-inhibitors eculizumab or ravulizumab: results from a US patient

survey. Ann Hematol. 2022;101(2):251-263.

8. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal

haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028.

9. Röth A, Maciejewski J, Nishimura JI, Jain D, Weitz JI. Screening and

diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria:

Expert consensus. Eur J Haematol. 2018;101(1):3-11.

10. Levy AR, Dysart L, Patel Y, et al. Comparison of Lost Productivity Due to

Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal

Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United

Kingdom, and the United States. Blood. 2019;134(Supplement_1):4803.

11. McKinley CE, Richards SJ, Munir T, et al. Extravascular Hemolysis Due to

C3-Loading in Patients with PNH Treated with Eculizumab: Defining the

Clinical Syndrome. Blood. 2017;130(Supplement 1):3471.

12. Risitano AM, Marotta S, Ricci P, et al. Anti-complement Treatment for

Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement

Inhibition? A Position Paper From the SAAWP of the EBMT. Front Immunol.

2019;10:1157.

13. Shammo J, Kim J, Georget M, et al. P796: Hospitalization in patients with

paroxysmal nocturnal hemoglobinuria: a retrospective analysis of

observational study data from the United States. Hemasphere.

2023;7(Suppl):e22585a2.

14. Debureaux PE, Kulasekararaj AG, Cacace F, et al. Categorizing

hematological response to eculizumab in paroxysmal nocturnal

hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant.

2021;56(10):2600-2602.

15. Schrezenmeier H, Kulasekararaj A, Mitchell L, et al. One-year efficacy

and safety of ravulizumab in adults with paroxysmal nocturnal

hemoglobinuria naïve to complement inhibitor therapy: open-label

extension of a randomized study. Ther Adv Hematol.

2020;11:2040620720966137.

16. Young NS, Meyers G, Schrezenmeier H, Hillmen P, Hill A. The management of

paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and

treatment and new hope for patients. Semin Hematol. 2009;46(1 Suppl

1):S1-S16.

17. Risitano AM, Araten DJ, Kuter D, et al. Pb2063: APPULSE-PNH: A phase IIIB

trial to evaluate the efficacy and safety of switching to iptacopan in

patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti-c5

therapy with hemoglobin >10g/dl. Hemasphere. 2023;7(Suppl):e08587b7.

18. Clinicaltrials.gov. NCT04558918. Study of Efficacy and Safety of Twice

Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite

Anti-C5 Antibody Treatment (APPLY-PNH). Available from:

https://clinicaltrials.gov/study/NCT04558918 Accessed May, 2025.

19. Risitano AM, Han B, Ueda Y, et al. Oral Complement Factor B Inhibitor

Iptacopan Monotherapy Improves Hemoglobin to Normal/Near-Normal Levels in

Paroxysmal Nocturnal Hemoglobinuria Patients Naïve to Complement

Inhibitors: Phase III APPOINT-PNH Trial. Presented at: 49th Annual

Meeting of the European Society for Blood and Marrow Transplantation

(EBMT); April 23-36, 2023; Paris, France.

20. Clinicaltrials.gov. NCT04820530. Study of Efficacy and Safety of Twice

Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to

Complement Inhibitor Therapy (APPOINT-PNH). Available from:

https://clinicaltrials.gov/study/NCT04820530 Accessed May, 2025.

21. Kavanagh D, Bomback A, Vivarelli M, et al. Efficacy and Safety of

Iptacopan in Patients with C3 Glomerulopathy: Results from the Phase 3

APPEAR-C3G Trial. Presented at European Renal Association (ERA) Congress;

May 25, 2024; Stockholm, Sweden.

22. Smith RJ, Kavanagh D, Vivarelli M, et al. Efficacy and safety of

iptacopan in patients with C3 glomerulopathy: 12-Month results from the

Phase 3 APPEAR-C3G study. Presented at American Society of Nephrology

(ASN) Kidney Week 2024; October 23-27, 2024; San Diego, CA.

23. Novartis. Press release. Novartis receives FDA approval for Fabhalta(R)

(iptacopan), offering superior hemoglobin improvement in the absence of

transfusions as the first oral monotherapy for adults with PNH. Available

from:

https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-absence-transfusions-first-oral-monotherapy-adults-pnh

Accessed May, 2025.

24. Novartis. Press release. Novartis receives FDA accelerated approval for

Fabhalta(R) (iptacopan), the first and only complement inhibitor for the

reduction of proteinuria in primary IgA nephropathy (IgAN). Available

from:

https://www.novartis.com/news/media-releases/novartis-receives-fda-accelerated-approval-fabhalta-iptacopan-first-and-only-complement-inhibitor-reduction-proteinuria-primary-iga-nephropathy-igan

Accessed May, 2025.

25. Novartis. Press release. Novartis receives third FDA approval for oral

Fabhalta(R) (iptacopan) -- the first and only treatment approved in C3

glomerulopathy (C3G). Available from:

https://www.novartis.com/news/media-releases/novartis-receives-third-fda-approval-oral-fabhalta-iptacopan-first-and-only-treatment-approved-c3-glomerulopathy-c3g

Accessed May, 2025.

26. Novartis. Press release. Novartis oral Fabhalta(R) (iptacopan) receives

positive CHMP opinion for the treatment of adults living with C3

glomerulopathy (C3G). Available from:

https://www.novartis.com/news/media-releases/novartis-oral-fabhalta-iptacopan-receives-positive-chmp-opinion-treatment-adults-living-c3-glomerulopathy-c3g

Accessed May, 2025.

27. Fabhalta(R). US FDA Prescribing information. East Hanover, NJ:Novartis

Pharmaceuticals Corp; 2024. Available

from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218276s00

1lbl.pdf Accessed May, 2025.

28. Fabhalta(R). EMA Summary of Product Characteristics. Novartis Europharm

Limited; 2024. Available from:

https://www.ema.europa.eu/en/documents/product-information/fabhalta-epar-product-information_en.pdf

Accessed May, 2025.

29. Martín B, Smith RJH. C3 Glomerulopathy. In: Adam MP, Feldman J,

Mirzaa GM, et al, eds. GeneReviews(R) [Internet]. Seattle, WA: University

of Washington, Seattle; 1993-2025. Updated April 5, 2018. Available from:

https://www.ncbi.nlm.nih.gov/books/NBK1425/ Accessed May, 2025.

30. Schena FP, Esposito P, Rossini M. A Narrative Review on C3

Glomerulopathy: A Rare Renal Disease. Int J Mol Sci. 2020;21(2):525.

31. Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Update on C3

Glomerulopathy: A Complement-Mediated Disease. Nephron.

2020;144(6):272-280.

32. Clinicaltrials.gov. NCT04578834. Study of Efficacy and Safety of LNP023

in Primary IgA Nephropathy Patients (APPLAUSE-IgAN). Available from:

https://clinicaltrials.gov/study/NCT04578834 Accessed May, 2025.

33. Clinicaltrials.gov. NCT04889430. Efficacy and Safety of Iptacopan

(LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive

to Complement Inhibitor Therapy (APPELHUS). Available from:

https://clinicaltrials.gov/study/NCT04889430 Accessed May, 2025.

34. Clinicaltrials.gov. NCT05755386. Study of Efficacy and Safety of

(MORE TO FOLLOW) Dow Jones Newswires

June 12, 2025 02:00 ET (06:00 GMT)